Incyte Corporation

Joshua Hummel

Wenqing Yao

Oleg Vechorkin

Alexander Sokolsky

Qinda Ye

Kai Liu

Ding-Quan Qian

Liangxing Wu

Jun Pan

Jingwei Li

Hai Fen Ye

Xiaozhao Wang

David M Burns

Meizhong Xu

Fenglei Zhang

Zhenwu Li

Kaijiong Xiao

Minh Nguyen

Yingnan Chen

Min Ye

Margaret Favata

Yvonne Lo

Jeffrey C Yang

The present application provides bicyclic amines of Formula (I): or a pharmaceutically acceptable salt thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.

Bicyclic pyrazolyl amines as CDK2 inhibitors

The present application provides bicyclic amines of Formula (I): and their pharmaceutically acceptable salts thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.

Bicyclic amines as CDK2 inhibitors

Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.

Benzothiazole compounds and uses thereof

Pyrazolopyrimidine compounds and uses thereof

The present application provides pyrazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.

Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors

Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer. 

Benzimidazole and indole compounds and uses thereof

Growing community of inventors

Hockessin, DE, United States of America

Joshua Hummel